The front line market potential is >$2 billion and growing. The problem is ponatinib would be facing competition against second generation agents like Tasigna and Sprycel, and against Gleevec which would be available as a generic by the time Ariad completes a head-to-head phase III trial.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.